MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
23.15
-0.17
-0.73%
After Hours: 23.10 -0.05 -0.22% 17:29 02/04 EST
OPEN
23.32
PREV CLOSE
23.32
HIGH
23.44
LOW
22.69
VOLUME
2.27M
TURNOVER
--
52 WEEK HIGH
30.60
52 WEEK LOW
16.10
MARKET CAP
2.93B
P/E (TTM)
77.95
1D
5D
1M
3M
1Y
5Y
1D
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
NASDAQ · 1d ago
Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
TipRanks · 1d ago
Weekly Report: what happened at APLS last week (0126-0130)?
Weekly Report · 2d ago
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors
Simply Wall St · 4d ago
Apellis Pharmaceuticals (APLS) Valuation Check As Shares Trade Around US$23 After Mixed Return Performance
Simply Wall St · 6d ago
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga · 01/28 13:41
Apellis Pharmaceuticals Initiated at Equal-Weight by Barclays
Dow Jones · 01/28 13:23
Apellis Pharmaceuticals Price Target Announced at $24.00/Share by Barclays
Dow Jones · 01/28 13:23
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.